Activated Protein C (390-404), human, a peptide derived from the vitamin K-dependent serine protease, effectively suppresses the anticoagulant activity of APC[1].
Calmodulin-Dependent ProteinKinase II (290-309) is a potent CaMK antagonist with an IC50 of 52 nM for inhibiting Ca2+ calmodulin-dependent proteinkinase II.
ProteinKinase C (19-31) TFA 是蛋白激酶 C (PKC)的抑制剂,是由 PKCa (残基 19-31) 伪底物调控域衍生而来,25 位丝氨酸取代野生型丙氨酸作为蛋白激酶 C 底物肽,用于检测蛋白激酶 C 的活性。Proteinkinase C (PKC) TFA 通过磷酸化丝氨酸和苏氨酸氨基酸残基上的羟基来调控其它蛋白的功能。
COVID-19 Spike Protein mRNA-LNP 是一种RNA传递系统,利用脂质纳米粒(LNP)封装COVID-19 Spike Protein mRNA,提高翻译效率与细胞活性。COVID-19 Spike Protein,位于新冠病毒膜表面,负责与宿主细胞受体结合和膜融合,是病毒进入细胞的关键因素,同时也是疫苗设计与宿主中和抗体生成的核心靶点。
ProteinKinase Inhibitors 1 Hydrochloride effectively inhibits HIPK2, demonstrating high potency with IC50 values of 136 nM for HIPK1 and 74 nM for HIPK2, alongside a dissociation constant (Kd) of 9.5 nM for HIPK2.
Calmodulin-Dependent ProteinKinase II (281-309) is a synthetic peptide phosphorylatable at Thr286 by PKC, inhibiting CaM kinase II with an IC50 of 80 nM.
C-Reactive Protein (CRP) 77-82 is the 77-82 fragment of the annular (ring-shaped) C-Reactive Protein, the prototypic marker of inflammation, which serves as a cardiovascular risk marker and may promote atherogenesis.
Proteinkinase D inhibitor 1 (compound 17m) is a potent pan-PKD inhibitor. It exhibits inhibitory activity in the low nanomolar range, with IC50 values ranging between 17 and 35 nM. By inhibiting proteinkinase D, this compound effectively suppresses cortactin phosphorylation, which is known to be PKD-dependent [1].
ProteinKinase C (19-31), a peptide inhibitor of proteinkinase C (PKC) derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as a proteinkinase C substrate peptide.
The peptide region containing residues 390-404 in Activated Protein C (APC) is essential for anticoagulant activity and is available for interaction with antibodies or with other proteins, such as the macromolecular substrates Factors Va or VIIIa. APC reg
ProteinKinase C (19-31) TFA, a peptide inhibitor of proteinkinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as proteinkinase C substrate p